Pfizer Targets Wockhardt In Generic Toviaz Suit
According to Pfizer, Wockhardt USA LLC's plans to make fesoterodine fumarate extended-release tablets infringes five patents covering Topiaz's active ingredient — U.S. Patent Numbers 6,858,650; 7,384,980; 7,855,230; 7,985,772; and 8,338,478 — which are exclusively licensed to Pfizer by UCB Pharma GmbH.
“Plaintiffs will be harmed substantially and irreparably if Wockhardt is not enjoined from infringing...
Already a subscriber? Click here to login